Cyclacel Pharmaceuticals, Inc. (CYCC)

NASDAQ: CYCC · IEX Real-Time Price · USD
2.785
+0.155 (5.89%)
Feb 26, 2024, 11:50 AM EST - Market open

Company Description

Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases.

The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors.

It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias.

The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey.

Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals logo
Country United States
Founded 1992
Industry Biotechnology
Sector Healthcare
Employees 12
CEO Spiro George Rombotis

Contact Details

Address:
200 Connell Drive, Suite 1500
Berkeley Heights, New Jersey 07922
United States
Phone 908-517-7330
Website cyclacel.com

Stock Details

Ticker Symbol CYCC
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001130166
CUSIP Number 23254L603
ISIN Number US23254L8019
Employer ID 91-1766850
SIC Code 2834

Key Executives

Name Position
Spiro George Rombotis President, Chief Executive Officer and Executive Director
Paul McBarron Executive Vice President of Finance, Chief Financial Officer, Chief Operating Officer, Secretary and Executive Director
Gill Christie Director of Human Resources
Dr. Brian Schwartz M.D. Chief Medical Officer and Director

Latest SEC Filings

Date Type Title
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024 424B3 Prospectus
Feb 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 13, 2024 EFFECT Notice of Effectiveness
Feb 13, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Feb 8, 2024 S-1/A [Amend] General form for registration of securities under the Securities Act of 1933
Feb 7, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Jan 30, 2024 8-K Current Report
Jan 19, 2024 S-1 General form for registration of securities under the Securities Act of 1933
Jan 12, 2024 8-K Current Report